Who is sponsoring NCT07122258?

NCT07122258 is sponsored by Tau Medical Australia Pty Ltd.

What drugs are being tested in NCT07122258?

Interventions in NCT07122258: CAROL NSCLC treatment Device.

What condition does NCT07122258 study?

NCT07122258 studies NSCLC (Non-small Cell Lung Cancer).

Is NCT07122258 still recruiting?

NCT07122258 is currently recruiting now. Last updated 5 March 2026.

Last reviewed 2026-03-05 · How we verify

NCT07122258

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Early Feasibility Study (EFS) of the 'CAROL' for Treatment of Lung Cancer Stage 1

Recruiting now NA Last updated 5 March 2026

What this trial tests

NA trial testing CAROL NSCLC treatment Device in NSCLC (Non-small Cell Lung Cancer) in 7 participants. Currently enrolling.

Timeline

1 March 2026

Primary endpoint
1 March 2027

1 June 2027

Quick facts

Lead sponsor	Tau Medical Australia Pty Ltd
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	7
Start date	1 March 2026
Primary completion	1 March 2027
Estimated completion	1 June 2027
Sites	1 location across Australia

Drugs / interventions tested

CAROL NSCLC treatment Device

Conditions studied

NSCLC (Non-small Cell Lung Cancer) — all drugs for NSCLC (Non-small Cell Lung Cancer) →

Sponsor

Tau Medical Australia Pty Ltd — full company profile →

Who can join

18 and older, any sex, with NSCLC (Non-small Cell Lung Cancer). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate the safety of the CAROL device for treating lung tumors in patients diagnosed with non-small cell lung cancer (NSCLC) with tumor size ≤ 2 cm (cT1b). The primary objective is to assess safety by monitoring and grading adverse events using the CTCAE v5.0 criteria at one month following the procedure.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for NSCLC (Non-small Cell Lung Cancer)

Currently open trials in the same condition.

NCT07528274 — Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure · Phase 2 · recruiting
NCT07354061 — Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC) · Phase 1, PHASE2 · recruiting
NCT07441941 — Single-Fraction Pulmonary Ablative Radiotherapy Outcomes and Quality-of-life Workup · recruiting
NCT07330050 — WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC · Phase 2 · recruiting
NCT07120698 — Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung) · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07122258 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tau Medical Australia Pty Ltd
Last refreshed: 5 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07122258.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing